Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04810858 · ClinicalTrials.gov registry record · NA

Modeling the Effects of Chronic Marijuana Use on Neuroinflammation and HIV-related Neuronal Injury

A NA study of HIV and Inflammation, sponsored by Wake Forest University Health Sciences.

Recruiting
Registry status
NA
Development phase
220
Enrollment target
1
Study location

NCT04810858: Recruiting NA study of HIV and Inflammation, sponsored by Wake Forest University Health Sciences.

NCT04810858 is a NA study of HIV and Inflammation that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 220 participants, below the 439-participant average among 303 other HIV trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04810858, a NA study of HIV and Inflammation, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.

RECRUITING
Registry status
NA
Development phase
220 participants
Enrollment target
1
Study location

Study Summary

This study applies a hypothesis-driven approach to examine the effects of chronic marijuana use on HIV-associated inflammation and its subsequent impacts on central nervous system function, with the goal of identifying the mechanisms through which cannabinoids modulate neurological disorders and other comorbidities in persons with HIV.

Primary Outcome

The neuropsychological testing battery assesses 7 cognitive domains with 3-4 tests per domain. Raw scores from each test will be converted to demographically adjusted standard scores, called T-scores using up-to-date US normative data. A T-score of 50 is considered the normative mean, and each 10-point deviation is equivalent to 1 standard deviation. The minimum possible T-score is 0 and the maximum is 100, with higher scores meaning better neurocognitive function. The average T-score for all te

Interventions

  • OTHER Multimodal, multi-parametric MRI
  • OTHER Immune and cytokine profiling
  • BEHAVIORAL Neuropsychological testing

Study Locations (1)

North Carolina

  • Biotech Place - Winston-Salem

Trial Details

FieldValue
Enrollment Target 220 participants
Start Date 2021-08-18
Est. Completion 2026-05-31
Phase NA
Wake Forest University Health Sciences

1,140 total trials

What NCT04810858 shows while recruiting

NCT04810858 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 439-participant average among 303 other HIV trials with a reported enrollment target (50% lower).

The record links to 5 conditions, with HIV appearing as the primary indexed condition, and to 3 interventions - of which Multimodal, multi-parametric MRI is the first listed.

NCT04810858 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT04810858 about?

NCT04810858 is a clinical study titled "Modeling the Effects of Chronic Marijuana Use on Neuroinflammation and HIV-related Neuronal Injury". This study applies a hypothesis-driven approach to examine the effects of chronic marijuana use on HIV-associated inflammation and its subsequent impacts on central nervous system function, with the goal of identifying the mechanisms through which cannabinoids modulate neurological disorders and oth...

What is the current status of trial NCT04810858?

This trial is currently recruiting. It is a NA study. The enrollment target is 220 participants. The study started on 2021-08-18. Estimated completion is 2026-05-31.

What conditions does trial NCT04810858 study?

This clinical trial studies the following conditions: HIV, Inflammation, Cognition, Cannabis, Neuroimaging.

What interventions are being tested in trial NCT04810858?

The interventions under investigation include: Multimodal, multi-parametric MRI (OTHER), Immune and cytokine profiling (OTHER), Neuropsychological testing (BEHAVIORAL).

Who is sponsoring clinical trial NCT04810858?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04810858 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04810858's enrollment target sits among peer trials

220 96th of 303 higher than 208 of 303 other HIV trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00920972 · 220 participants · Phase 1

    Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

  • NCT01851642 · 220 participants

    Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs

  • NCT02582021 · 220 participants

    WISE CVD - Continuation (WISE HFpEF)

  • NCT04067830 · 220 participants · Phase 2

    Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04810858, the US trial registry maintained by the National Library of Medicine. NCT04810858 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.